We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Laborde Professor for Cancer Research; Medical Director, Tulane Cancer Center; Associate Dean for Oncology, Tulane School of Medicine, New Orleans, Louisiana

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three phase III studies pivotal for FDA approval. He has lectured widely, and at last count has given invited lectures in 33 countries.

He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology) and is co-PI of the VISION trial, an international phase III study of Lu-177 PSMA in advanced prostate cancer.

Disclosures

CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.

Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.

Recent Contributions to PracticeUpdate:

  1. Outcomes of Adding ADT and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy for Prostate Cancer
  2. ASCO 2022: Abstract Recommendations From Dr. Oliver Sartor for Prostate Cancer
  3. Niraparib in Combination With Abiraterone Acetate and Prednisone vs Abiraterone Acetate and Prednisone for Treatment of Metastatic Prostate Cancer
  4. Darolutamide and Survival in Prostate Cancer
  5. Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-Resistant Prostate Cancer
  6. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
  7. Darolutamide in Metastatic and Hormone-Sensitive Prostate Cancer
  8. 2021 Top Story in Advanced Prostate Cancer: The Promise of PSMA PET
  9. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
  10. Fracture Risk and Radium-223 for Metastatic Prostate Cancer

Most Read This Week

Recently Updated